(Repeats story, text unchanged)
* Ebola emergency demands speed, more risk in vaccine tests
* Vaccines will be evaluated at same time as being deployed
* Issues of placebos and control groups need consideration
* WHO sees small-scale vaccine use in W. Africa by Jan 2015
By Kate Kelland, Health and Science Correspondent
LONDON, Sept 28 (Reuters) - Normally it takes years to prove a new vaccine is both safe and effective before it can be used in the field. But with hundreds of people dying a day in the worst ever outbreak of Ebola, there is no time to wait.
In an effort to save lives, health authorities are determined to roll out potential vaccines within months, dispensing with some of the usual testing, and raising unprecedented ethical and practical questions.
“Nobody knows yet how we will do it. There are lots of tough real-world deployment issues and nobody has the full answers yet,” said Adrian Hill, who is conducting safety trials on healthy volunteers of an experimental Ebola shot developed by GlaxoSmithKline.
Hill, a professor and director at the Jenner Institute at Britain’s University of Oxford, says that if his results show no adverse side-effects, GSK’s new shot could used in people in West Africa by the end of this year.
Even if a drug is shown to be safe, it takes longer to prove it is effective - time that is simply not available when cases of Ebola infection are doubling every few weeks and projected by the World Health Organization to reach 20,000 by November.
Among questions that scientists are grappling with: should an unproven vaccine be given to everybody, or just a few? Should it be offered to healthcare workers first? The young before the old? Should it be used first in Liberia where Ebola is spreading fastest, or Guinea where it is closer to being under control?
Should people be told to assume it will protect them from Ebola? Or should they take all the protective measures they would if they hadn’t been vaccinated? And if so, how will anyone know whether the vaccine works?
GSK is one of several drug firms that have either started or announced plans for human trials of candidate Ebola vaccines. Others include Johnson & Johnson, NewLink, Inovio Pharmaceuticals and Profectus Biosciences.
The WHO says it hopes to see small-scale use of the first experimental Ebola vaccines in the West Africa outbreak by January next year.
It has convened vaccine specialists, epidemiologists, pharmaceutical companies and ethicists, for a meeting on Monday and Tuesday to discuss the moral and practical issues.
“Normally safety is the absolutely paramount thing when you’re developing a new vaccine, but this time we’re going to have to take more risks,” said Brian Greenwood, a professor at the London School of Hygiene and Tropical Medicine who will take part in the WHO-led meeting.
“Quite how we do that, and what risks we take, hasn’t really been thought through yet. That’s what people are trying to figure out.”
The chaos caused by the epidemic itself makes it even more difficult to deploy and track use of a new vaccine, said Hill.
“You’re trying to do two things at the same time: you’re trying to evaluate a vaccine and deploy it - when normally you would evaluate the vaccine first, by doing a randomised double blind controlled trial, and then you’d deploy it if it was shown to be safe and effective.”
Because Ebola virus is so deadly, those who receive a trial vaccine must be told to take all other precautions and protect themselves fully. This could make it harder for researchers to decipher whether the protective clothing and safety protocols, or the new vaccine, is what kept them safe.
Normally researchers testing a vaccine would give some volunteers a placebo, or dummy, to create a “control” group to compare against those who get the real drug. That seems unthinkable in a situation where disease with a death rate of up to 90 percent is raging through villages.
“Would it be ethical to do a trial where some people don’t get the vaccine because they are in the control group? Most people think it wouldn’t be - especially if you have reasonable evidence that the vaccine might work,” said Hill.
Jeremy Farrar, an infectious diseases expert and director of the Wellcome Trust medical charity, said limited supplies of any candidate vaccine could result in a form of natural control group being formed anyway. Researchers can compare populations where the vaccine is available with those where it isn‘t.
GSK has said it is aiming to have 10,000 doses of its experimental shot by the end of the year, while Canada has given 800 vials of the NewLink candidate vaccine to the WHO, expected to yield at least 1,500 doses.
Most experts interviewed by Reuters favour the idea of the first doses going to frontline healthcare workers, since their exposure to risk is so high. Researchers could then compare infection rates among health workers who receive the vaccine to those working in regions still waiting for it.
Peter Piot, a co-discoverer of the Ebola virus in 1976 and now director of the London School of Hygiene and Tropical Medicine said that however complicated the ethics, reverting to the traditional years-long process of testing vaccines, and withholding them from West Africa until then, is not an option.
“It may be that without a vaccine, we can’t really stop this epidemic,” he said. (Reporting by Kate Kelland; Editing by Peter Graff)